Becton, Dickinson and Company $BDX Shares Sold by Advisors Capital Management LLC

Advisors Capital Management LLC cut its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 8.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,320 shares of the medical instruments supplier’s stock after selling 119 shares during the period. Advisors Capital Management LLC’s holdings in Becton, Dickinson and Company were worth $303,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in BDX. Saudi Central Bank acquired a new stake in Becton, Dickinson and Company during the first quarter valued at approximately $26,000. Smallwood Wealth Investment Management LLC purchased a new stake in shares of Becton, Dickinson and Company in the 1st quarter valued at approximately $27,000. REAP Financial Group LLC lifted its position in shares of Becton, Dickinson and Company by 75.3% in the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after acquiring an additional 55 shares in the last quarter. Alpine Bank Wealth Management purchased a new stake in shares of Becton, Dickinson and Company in the 1st quarter valued at approximately $29,000. Finally, Cornerstone Planning Group LLC lifted its position in shares of Becton, Dickinson and Company by 341.4% in the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after acquiring an additional 99 shares in the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Stock Performance

NYSE:BDX opened at $187.23 on Friday. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99. The firm’s fifty day simple moving average is $186.46 and its 200 day simple moving average is $191.49. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $53.66 billion, a PE ratio of 33.67, a PEG ratio of 1.42 and a beta of 0.27.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business had revenue of $5.51 billion for the quarter, compared to analyst estimates of $5.50 billion. During the same period last year, the business posted $3.50 EPS. Becton, Dickinson and Company’s revenue was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, sell-side analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be paid a $1.04 dividend. The ex-dividend date is Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 74.82%.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of the stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director directly owned 22,226 shares of the company’s stock, valued at $4,167,375. This represents a 3.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction on Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the sale, the executive vice president directly owned 4,887 shares of the company’s stock, valued at approximately $881,077.23. This trade represents a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 2,965 shares of company stock worth $551,536 over the last quarter. 0.36% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts recently commented on BDX shares. Morgan Stanley upped their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Wells Fargo & Company upped their price target on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research report on Friday, August 8th. Citigroup lowered shares of Becton, Dickinson and Company from a “strong-buy” rating to a “hold” rating and dropped their price objective for the company from $217.00 to $185.00 in a research note on Thursday, May 22nd. Piper Sandler reiterated a “neutral” rating and issued a $200.00 price objective (up previously from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Finally, Barclays dropped their price objective on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating on the stock in a research note on Tuesday, June 3rd. Four investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $211.44.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.